口服氯化汞对大鼠肾间质纤维化的作用

目的口服氯化汞(HgCl2)造成大鼠的肾间质纤维化模型并探讨相关机制。方法用不同剂量HgCl2[(A组为5mg/(kg·bw)、B组为10mg/(kg·bw)、C组为20mg/(kg·bw)]给大鼠灌胃1周,观察大鼠一般状况、肾功能和肾组织病理变化,免疫组化法观察肾组织纤维连接蛋白(FN)和α-平滑肌肌动蛋白(α-SMA)表达。结果模型大鼠体重下降,肾体比增加,肾功能损害和肾组织Hyp含量呈剂量依赖性升高,肾间质炎性细胞浸润,肾间质胶原沉积增加,肾间质FN和α-SMA表达增强,以C组病变最重。结论20mg/(kg·bw)剂量HgCl2灌胃1周可造成大鼠的肾间质纤维化病变,其部分机制在于HgCl2促使肾间质肌成纤维细胞活化和细胞外基质的生成沉积。     

上皮—间质转化在肾间质纤维化中的作用

上皮－间质转化在发育和纤维化过程中具有重要作用。本文综述了上皮－间质转化发生的过程及其机制的研究进展,尤其是细胞外基质、生长因子、粘附分子及基因对上皮－间质转化的影响。并就在肾间质纤维化过程中因上皮－间质转化致成纤维细胞增多,从而导致肾纤维化的可能作用及其影响因素作一述。     

脂代谢紊乱在肾脏衰老和肾纤维化中的作用

肾间质纤维化是终末期肾脏病的病理基础,肾脏衰老是肾间质纤维化的危险因素。越来越多的研究证明,脂代谢紊乱会导致肾脏衰老和肾间质纤维化。脂代谢紊乱引起的脂质堆积,会造成脂毒性和细胞应激性损伤,从而诱发衰老与细胞外基质（extracellular matrix,ECM）的分泌。维持脂代谢稳态有助于减轻肾脏衰老与肾间质纤维化的发生发展。脂代谢途径的关键酶和调控蛋白有望成为改善肾脏衰老和肾间质纤维化的潜在靶点。本综述概括了脂代谢紊乱在肾脏衰老和间质纤维化中的作用,并对脂代谢中肾脏衰老和间质纤维化的预防靶点和策略进行了总结,为治疗肾纤维化发现新靶点提供了参考。     

TNFRSF13C 在单侧输尿管梗阻大鼠肾组织中的表达及其意义

目的：检测单侧输尿管梗阻（UUO）大鼠肾组织中B 细胞激活因子受体（TNFRSF13C）的表达变化,探讨其在肾间质纤维化 病变中的作用。方法：采用UUO法建立肾间质纤维化大鼠模型,20只成年雄性大鼠,随机分为4组,分别于术后0、3、7、14 天处死 大鼠。取左侧梗阻肾脏进行Masson染色,拍照后,采用双盲法评定各组肾小管间质纤维化程度。提取肾组织中总RNA,用实时荧 光定量聚合酶链反应（RT-PCR）法检测各组肾组织中TNFRSF13C基因表达情况。Pearson 检测TNFRSF13C表达量与肾小管间质 纤维化程度的相关性。结果：随着梗阻时间的延长,肾组织中TNFRSF13C 的mRNA 表达量进行性升高,与肾间质纤维化病变程 度一致,两者呈显著正相关（r=0.915,P<0.01）。结论：TNFRSF13C可能在肾间质纤维化病程中起到了重要作用,并有望成为慢性 肾脏病的临床监测指标。     

苦参素对单侧输尿管梗阻大鼠肾间质纤维化的保护作用

目的探讨苦参素对单侧输尿管梗阻(UUO)大鼠肾间质纤维化的影响及可能机制。方法45只雄性SD大鼠随机分为3组:A假手术组,B单侧输尿管结扎(UUO)组,C治疗组。治疗组在UUO的基础上每天以苦参素100mg/Kg/d腹腔注射。B组和C组于术后第7,14,21,28分别处死5只大鼠,A组于第28天处死大鼠。用PAS及Masson染色法观察肾脏病理改变。用免疫组化法检测转化生长因子β1(transforming growth factor-beta1 TGF-β1),α-平滑肌肌动蛋白(alpha-smooth muscle actin-αSMA),Ⅰ型胶原(collagenⅠColⅠ)的表达。结果与UUO组相比,治疗组梗阻侧肾脏TGF-β1,-αSMA,ColⅠ的表达明显减少,肾小管损害和肾间质纤维化的程度也明显减轻。结论苦参素可通过下调TGF-β1,减少肾小管上皮细胞转分化而减轻肾间质纤维化。     

肾小球内皮细胞-间质转化在糖尿病肾病肾纤维化中的作用

肾纤维化是糖尿病肾病(diabetic kidney disease,DKD)重要的病理特征。肾小球内皮细胞-间质转化(endothelial-to-mesenchymal transition,EndoMT)可促进肾纤维化,在DKD的发生发展中起重要作用,但其具体机制仍有待研究。本文就EndoMT在DKD肾纤维化中的分子机制以及目前通过抗EndoMT治疗延缓DKD肾纤维化的研究进展作一综述,以期为DKD的临床治疗提供新的理论依据。     

不同热休克蛋白在肾细胞癌组织中的表达及其意义

目的　研究HSPgp96、HSP90、HSP70在肾细胞癌组织中的表达及其相互关系。方法　应用免疫组化S P法检测 5 4例肾细胞癌组织标本中HSPgp96、HSP90、HSP70的表达情况。结果　在肾细胞癌组织中HSPgp96、HSP90、HSP70表达明显较正常肾组织增强 (P <0 0 5 ) ,阳性率分别为 88 9%、 85 2 %、 90 7% ,三者之间无明显差异性 (P >0 0 5 ) ,其表达程度均与肾细胞癌临床分期、病理分级及细胞类型无显著相关性 (P >0 0 5 )。结论　HSPgp96、HSP90、HSP70的高表达在肾细胞癌的发生、发展中起促进作用 ,尤其是在加强肿瘤抗原的呈递、表达上具有重要临床应用价值。     

携带人肝细胞生长因子重组质粒pUDK-HGF对大鼠肾纤维化的防治作用

目的:研究肝细胞生长因子(HGF)基因转导对庆大霉素诱导的大鼠肾纤维化损伤的防治效果。方法:以雄性Wistar大鼠腹腔注射硫酸庆大霉素注射液制备肾纤维化模型;实验分为正常对照组、肾纤维化模型组、HGF治疗组;造模后第30 d,HGF治疗组于左侧肾脏直接注射重组质粒pUDK-HGF注射液,模型组注射质粒pUDK,正常对照组只进行假手术;于造模后第60 d处死大鼠,评价HGF对血尿素氮、血肌酐、24 h尿蛋白、肾系数等肾功能指标的改善作用,并对肾纤维化进行组织学评价。结果:与正常对照组相比,模型组肾功能下降,肾系数(8.8±0.95 g/kg)、血尿素氮(9.4±2.61 mmol/L)、血肌酐(42±10.33μmol/L,P<0.05)及24 h尿蛋白定量(25.78±8.66 mg,P<0.05)升高;HGF治疗组对肾功能有所改善,可缓解肾纤维化的进展。此外,本实验表明,对已纤维化肾脏直接注射HGF基因,可促进肾间质血管再生,并进一步降低肾小管间质损伤积分。结论:将HGF基因靶向导入大鼠体内可有效防治肾纤维化。     

巨噬细胞在小鼠肾纤维化恢复期的研究

目的:观察巨噬细胞在小鼠肾纤维化进展期和恢复期的作用。方法:采用单侧输尿管结扎(UUO)肾纤维化模型和输尿管再通模型(RUUO)进行试验研究;用Masson染色和HE染色观察肾脏纤维化程度和炎症变化趋势;流式分析肾脏中巨噬细胞细胞群的比例变化。结果:Masson染色显示肾脏纤维化程度在梗阻解除后胶原沉积面积减轻从80%降到46%,差异有统计学意义(P0.05)。HE染色显示梗阻解除后肾间质炎症减轻,且有新生小管形成。流式结果显示梗阻解除后巨噬细胞细胞群比例由19%降到2.6%,差异有统计学意义(P0.05)。结论:巨噬细胞可能在肾纤维化恢复期发挥一定作用。     

Ca2+/S100 Proteins Act as Upstream Regulators of the Chaperone-associated Ubiquitin Ligase CHIP (C Terminus of Hsc70-interacting Protein)

The U-box E3 ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein) binds Hsp90 and/or Hsp70 via its tetratricopeptide repeat (TPR), facilitating ubiquitination of the chaperone-bound client proteins. Mechanisms that regulate the activity of CHIP are, at present, poorly understood. We previously reported that Ca²⁺/S100 proteins directly associate with the TPR proteins, such as Hsp70/Hsp90-organizing protein (Hop), kinesin light chain, Tom70, FKBP52, CyP40, and protein phosphatase 5 (PP5), leading to the dissociation of the interactions of the TPR proteins with their target proteins. Therefore, we have hypothesized that Ca²⁺/S100 proteins can interact with CHIP and regulate its function. GST pulldown assays indicated that Ca²⁺/S100A2 and S100P bind to the TPR domain and lead to interference with the interactions of CHIP with Hsp70, Hsp90, HSF1, and Smad1. In vitro ubiquitination assays indicated that Ca²⁺/S100A2 and S100P are efficient and specific inhibitors of CHIP-mediated ubiquitination of Hsp70, Hsp90, HSF1, and Smad1. Overexpression of S100A2 and S100P suppressed CHIP-chaperone complex-dependent mutant p53 ubiquitination and degradation in Hep3B cells. The association of the S100 proteins with CHIP provides a Ca²⁺-dependent regulatory mechanism for the ubiquitination and degradation of intracellular proteins by the CHIP-proteasome pathway.     

C331A Mutant of Neuronal Nitric-oxide Synthase Is Labilized for Hsp70/CHIP (C Terminus of HSC70-interacting Protein)-dependent Ubiquitination

It is established that suicide inactivation of neuronal nitric-oxide synthase (nNOS) by drugs and other xenobiotics leads to ubiquitination and proteasomal degradation of the enzyme. The exact mechanism is not known, although it is widely thought that the covalent alteration of the active site during inactivation triggers the degradation. A mechanism that involves recognition of the altered nNOS by Hsp70 and its cochaperone CHIP, an E3-ubiquitin ligase, has been proposed. To further address how alterations of the active site trigger ubiquitination of nNOS, we examined a C331A nNOS mutant, which was reported to have impaired ability to bind l-arginine and tetrahydrobiopterin. We show here that C331A nNOS is highly susceptible to ubiquitination by a purified system containing ubiquitinating enzymes and chaperones, by the endogenous ubiquitinating system in reticulocyte lysate fraction II, and by intact HEK293 cells. The involvement of the altered heme cleft in regulating ubiquitination is confirmed by the finding that the slowly reversible inhibitor of nNOS, N^G-nitro-l-arginine, but not its inactive d-isomer, protects the C331A nNOS from ubiquitination in all these experimental systems. We also show that both Hsp70 and CHIP play a major role in the ubiquitination of C331A nNOS, although Hsp90 protects from ubiquitination. Thus, these studies further strengthen the link between the mobility of the substrate-binding cleft and chaperone-dependent ubiquitination of nNOS. These results support a general model of chaperone-mediated protein quality control and lead to a novel mechanism for substrate stabilization based on nNOS interaction with the chaperone machinery.     

C-terminus of Hsc70-interacting protein regulates profilin1 and breast cancer cell migration

Profilin1 (Pfn1) is a key mediator of actin polymerization and regulates cell migration. Low expression of Pfn1 is implicated in tumorigenesis of various cancers, including breast cancer. The regulatory mechanism behind Pfn1 levels has not yet been elucidated. In the present study, we find that Pfn1 is poly-ubiquitinated in human cell lines, and a portion of poly-ubiquitinated Pfn1 is regulated in a proteasome-dependent manner. C-terminus of Hsc70-interacting protein (CHIP), a co-chaperone E3 ligase, interacts with and ubiquitinates Pfn1, targeting it for proteasome-dependent degradation. Depletion of CHIP stabilizes Pfn1, suggesting that CHIP functions as a major E3 ligase for Pfn1. Stable expression of wild-type CHIP in the breast cancer cell line MDA-MB231 yielded downregulation of Pfn1 and enhanced cell migration. Pfn1 overexpression in MDA-MB231 cells expressing wild-type CHIP suppressed the enhanced cell migration. Taken together, our results demonstrate that CHIP regulates Pfn1 levels as an E3 ligase, and possibly plays a role in cell migration and metastasis of breast cancer.     

大鼠热休克蛋白70的融合表达及纯化鉴定

目的：在大肠杆菌中高效表达并纯化大鼠热休克蛋白（HSP）70与麦芽糖结合蛋白（MBP）的融合蛋白,以进一步研究细胞外HSfr70的生物学功能。方法：用RT-PCR方法扩增目的基因,并将其克隆到原核表达载体pMAL-c2X中,酶切鉴定并进行DNA测序;将该重组表达载体转化大肠杆菌B121,用IPTG在不同温度及时间下进行诱导表达,建立最佳诱导表达条件;采用Amylose树脂预装柱对目的蛋白进行亲和纯化,并对不同表达条件下的产物进行SDS-PAGE及Westernblot分析。结果：克隆出目的基因,构建了融合表达载体pMAL-c2X／hsp70;诱导表达后经SDS-PAGE检测表明获得了目的条带,并纯化出纯度较高的融合蛋白;免疫印迹鉴定表明其具有抗原活性。结论：在大肠杆菌中高效表达并纯化了融合蛋白MBP-HSP70,为进一步研究细胞外HSP70的生物学效应提供了有用的材料。     

Characteristics of Protein Carboxyl Methylation in the Rat Hypothalamus

Abstract: The formation of methyl-labeled S-adenosylmethionine (AdoMet) and methyl esters of endogenous methyl-acceptor proteins (MAPs) was studied in a synaptosomal preparation from the rat hypothalamus labeled with L-[methyl-³H]methionine. Incubation of synaptosomes with l -[methyl-³H]methi-onine resulted in a rapid labeling of the AdoMet pool and a less rapid formation of ³H-methyl-MAPs. Accumulation of ³H-methyl-MAPs was linear over a 30-min period. The effects of various inhibitors of AdoMet-dependent trans-methylation reactions on the formation of carboxylmethylated MAPs were examined. When hypothalamic synaptosomes were preincubated with l -[methyl-³H]methionine and subsequently incubated for 30 min in the presence of S-adenosyl-l -homocysteine (AdoHcy, 100 μm ), ³H-methyl-MAP formation was inhibited by approximately 70%. 100 μm -l -homocysteine thiolactone (HTL) as well as 100 μm -3-deazaadenosine (c³Ado) also caused a 60–70% inhibition of ³H-methyl-MAP formation; the combination of both c³Ado and HTL produced a slightly but not significantly greater inhibition than either agent alone. 10 μm -adenosine or 10 μm -HTL each produced an approximately 40% inhibition of ³H-methyl-MAP formation: the inhibitory effect of the two agents in combination was additive. Sinefungin and A9145C, potent inhibitors of bovine adrenomedullary protein carboxyl methylase, had no effect on ³H-methyl-MAP formation in hypothalamic synaptosomes at concentrations up to 1 mM. However, these compounds were potent inhibitors of ³H-methyl-MAP formation in lysed synaptosomes incubated with [³H-methyl]AdoMet. These results demonstrate that hypothalamic synaptosomes are capable of methio-nine activation and protein carboxyl methylation.     

The U-box ligase carboxyl-terminus of Hsc 70-interacting protein ubiquitylates Epsin

Epsin is an endocytic adaptor protein involved in the regulation of clathrin-dependent endocytosis. We and others have demonstrated that Epsin is ubiquitylated in cells and requires its ubiquitin interacting motifs (UIMs) for this modification. To further elucidate the mechanism of Epsin ubiquitylation, we initiated studies to identify the E3 ligase(s) that modifies Epsin. In this study, we discovered that the U-box ubiquitin ligase carboxyl-terminus of Hsc70 interacting protein (CHIP) ubiquitylated Epsin. Using an in vitro ubiquitylation assay, we demonstrate that CHIP specifically ubiquitylated Epsin in a UIM-dependent manner. Furthermore, overexpression of CHIP in cells increased Epsin ubiquitylation also in a UIM-dependent manner. Together, these data provide evidence that CHIP functions to ubiquitylate the endocytic protein Epsin.     

Cross-functional E3 ligases Parkin and C-terminus Hsp70-interacting protein in neurodegenerative disorders

The study of neurodegenerative disorders has had a major impact on our understanding of more fundamental mechanisms underlying neurobiology. Breakthroughs in the genetics of Alzheimer's (AD) and Parkinson's diseases (PD) has resulted in new knowledge in the areas of axonal transport, energy metabolism, protein trafficking/clearance and synaptic physiology. The major neurodegenerative diseases have in common a regional or network pathology associated with abnormal protein accumulation(s) and various degrees of motor or cognitive decline. In AD, β-amyloids are deposited in extracellular diffuse and compacted plaques as well as intracellularly. There is a major contribution to the disease by the co-existence of an intraneuronal tauopathy. Additionally, PD-like Lewy Bodies (LBs) bearing aggregated α-synuclein is present in 40-60% of all AD cases, especially involving amygdala. Amyloid deposits can be degraded or cleared by several mechanisms, including immune-mediated and transcytosis across the blood-brain barrier. Another avenue for disposal involves the lysosome pathway via autophagy. Enzymatic pathways include insulin degradative enzyme and neprilysin. Finally, the co-operative actions of C-terminus Hsp70 interacting protein (CHIP) and Parkin, components of a multiprotein E3 ubiquitin ligase complex, may be a portal to proteasome-mediated degradation. Mutations in the Parkin gene are the most common genetic link to autosomal recessive Parkinson's disease. Parkin catalyzes the post-translational modification of proteins with polyubiquitin, targeting them to the 26S proteasome. Parkin reduces intracellular Aβ(1-42) peptide levels, counteracts its effects on cell death, and reverses its effect to inhibit the proteasome. Additionally, Parkin has intrinsic cytoprotective activity to promote proteasome function and defend against oxidative stress to mitochondria. Parkin and CHIP are also active in amyloid clearance and cytoprotection in vivo. Parkin has cross-functionality in additional neurodegenerative diseases, for instance, to eliminate polyglutamine-expanded proteins, reducing their aggregation and toxicity and reinstate proteasome function. The dual actions of CHIP (molecular co-chaperone and E3 ligase) and Parkin (as E3-ubiquitin ligase and anti-oxidant) may also play a role in suppressing inflammatory reactions in animal models of neurodegeneration. In this review, we focus on the significance of CHIP and Parkin as inducers of amyloid clearance, as cytoprotectants and in the suppression of reactive inflammation. A case is made for more effort to explore whether neurodegeneration associated with proteinopathies can be arrested at early stages by promoting their mutual action.     

Regulation of fragile X mental retardation 1 protein by C-terminus of Hsc70-interacting protein depends on its phosphorylation status

The fragile X mental retardation 1 (FMR1) protein binds mRNA and acts as a negative regulator of translation. Lack of FMR1 causes the most common neurological disorder, fragile X syndrome, while its overexpression is associated with metastasis of breast cancer. Its activity has been well-studied in nervous tissue, but recent evidence as well as its role in cancer indicates that it also acts in other tissues. We have investigated the expression of FMR1 in brain and other tissues of mouse and examined its regulation. We detected expression of FMR1 in liver and heart tissues of mice as well as in brain tissue, supporting other contentions that it acts in non-nervous tissue. Expression of FMR1 inversely correlated with expression of the C-terminus of Hsc70-interacting protein (CHIP) and, based on the known activity of CHIP in protein homeostasis, we suggest that CHIP regulates expression of FMR1. CHIP ubiquitinated FMR1 for proteasomal degradation in a molecular chaperone-independent manner. FMR1 expression was reduced following treatment with okadaic acid, a phosphatase inhibitor, but not in CHIP-depleted cells. Also, a non-phospho FMR1 mutant was much less efficiently ubiquitinated by CHIP and had a longer half-life compared to either wild-type FMR or a phospho-mimic mutant. Taken together, our results demonstrate that CHIP regulates the levels of FMR1 as an E3 ubiquitin ligase in phosphorylation-dependent manner, suggesting that CHIP regulates FMR1-mediated translational repression by regulating the levels of FMR1.